BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 19625715)

  • 1. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Sur D; Ochiai RL; Bhattacharya SK; Ganguly NK; Ali M; Manna B; Dutta S; Donner A; Kanungo S; Park JK; Puri MK; Kim DR; Dutta D; Bhaduri B; Acosta CJ; Clemens JD
    N Engl J Med; 2009 Jul; 361(4):335-44. PubMed ID: 19625715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan.
    Khan MI; Soofi SB; Ochiai RL; Habib MA; Sahito SM; Nizami SQ; Acosta CJ; Clemens JD; Bhutta ZA;
    Vaccine; 2012 Aug; 30(36):5389-95. PubMed ID: 22721899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
    Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyphâ„¢) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population impact of Vi capsular polysaccharide vaccine.
    Khan MI; Ochiai RL; Clemens JD
    Expert Rev Vaccines; 2010 May; 9(5):485-96. PubMed ID: 20450323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design.
    Acosta CJ; Galindo CM; Ali M; Elyazeed RA; Ochiai RL; Danovaro-Holliday MC; Page AL; Thiem VD; Jin Y; Park JK; Lee H; Puri MK; Ivanoff B; Agtini MD; Soeharno R; Simanjuntak CH; Punjabi NH; Canh DG; Sur D; Nizami Q; Manna B; Bai-qing D; Anh DD; Honghui Y; Bhattacharya SK; Bhutta Z; Trach DD; Xu ZY; Pang T; Donner A; Clemens JD
    Trop Med Int Health; 2005 Dec; 10(12):1219-28. PubMed ID: 16359401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.
    Yang HH; Kilgore PE; Yang LH; Park JK; Pan YF; Kim Y; Lee YJ; Xu ZY; Clemens JD
    J Infect Dis; 2001 Jun; 183(12):1775-80. PubMed ID: 11372030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Vi vaccination on spatial patterns of typhoid fever in the slums of Kolkata, India.
    Ali M; Sur D; Kim DR; Kanungo S; Bhattacharya SK; Manna B; Ochiai RL; Clemens J
    Vaccine; 2011 Nov; 29(48):9051-6. PubMed ID: 21939716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
    Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
    Yang HH; Wu CG; Xie GZ; Gu QW; Wang BR; Wang LY; Wang HF; Ding ZS; Yang Y; Tan WS; Wang WY; Wang XC; Qin M; Wang JH; Tang HA; Jiang XM; Li YH; Wang ML; Zhang SL; Li GL
    Bull World Health Organ; 2001; 79(7):625-31. PubMed ID: 11477965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Typhim Vi vaccine in a postmarketing observational study.
    Marcus LC; Froeschle JE; Hill DR; Wolfe MS; Maus D; Connor B; Acosta AM; Rensimer ER; Roberts A; Dardick K
    J Travel Med; 2007; 14(6):386-91. PubMed ID: 17995534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
    Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
    [No Abstract]   [Full Text] [Related]  

  • 14. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Arya SC; Agarwal N
    N Engl J Med; 2009 Nov; 361(22):2191; author reply 2192-3. PubMed ID: 19940305
    [No Abstract]   [Full Text] [Related]  

  • 15. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya.
    Mirza NB; Wamola IA; Estambale BA; Mbithi E; Poillet M
    East Afr Med J; 1995 Mar; 72(3):162-4. PubMed ID: 7796767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for preventing typhoid fever.
    Milligan R; Paul M; Richardson M; Neuberger A
    Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
    J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Salmonella typhi Vi conjugate vaccine.
    Koul PA
    N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea.
    Lim SM; Jung HS; Kim MJ; Park DW; Kim WJ; Cheong HJ; Park SC; Lee KC; Shin YK; Tan HK; Kim SL; Sohn JW
    J Microbiol Biotechnol; 2007 Apr; 17(4):611-5. PubMed ID: 18051272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.